Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.

Holyoake DL, Ward E, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Patel N, Silva M, Mukherjee S, Strauss VY, Odondi L, Fokas E, Melcher A, Hawkins MA.

BMC Cancer. 2016 Sep 13;16(1):728. doi: 10.1186/s12885-016-2765-4.

2.

Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.

Åkerberg D, Ansari D, Andersson R.

World J Gastroenterol. 2016 Jul 28;22(28):6424-33. doi: 10.3748/wjg.v22.i28.6424. Review.

3.

Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia.

Hirakawa T, Yashiro M, Doi Y, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Kimura K, Amano R, Hirakawa K.

PLoS One. 2016 Aug 3;11(8):e0159912. doi: 10.1371/journal.pone.0159912. eCollection 2016.

4.

How Grim is Pancreatic Cancer?

Weledji EP, Enoworock G, Mokake M, Sinju M.

Oncol Rev. 2016 Jul 6;10(1):294. doi: 10.4081/oncol.2016.294. eCollection 2016 Apr 15. Review.

5.

Pancreatic Cancer from Molecular Pathways to Treatment Opinion.

Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG.

J Cancer. 2016 Jun 25;7(10):1328-39. doi: 10.7150/jca.15419. eCollection 2016. Review.

6.

Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

Russo S, Saif MW.

Therap Adv Gastroenterol. 2016 Jul;9(4):429-36. doi: 10.1177/1756283X16646524. Epub 2016 May 10. No abstract available.

7.

Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?

Sawicka E, Mirończuk A, Wojtukiewicz MZ, Sierko E.

Contemp Oncol (Pozn). 2016;20(2):102-8. doi: 10.5114/wo.2016.60066. Epub 2016 Jun 14. Review.

8.

Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis.

van Rijssen LB, Narwade P, van Huijgevoort NC, Tseng DS, van Santvoort HC, Molenaar IQ, van Laarhoven HW, van Eijck CH, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group.

HPB (Oxford). 2016 Jul;18(7):559-66. doi: 10.1016/j.hpb.2016.05.001. Epub 2016 May 27. Review.

9.

Tolerance and efficacy of palliative radiotherapy for advanced pancreatic cancer: A retrospective analysis of single-institutional experiences.

Wolny-Rokicka E, Sutkowski K, Grządziel A, Dorsz Ż, Tukiendorf A, Lipiński J, Wydmański J.

Mol Clin Oncol. 2016 Jun;4(6):1088-1092. Epub 2016 Apr 7.

10.

Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value.

Qiu M, Qiu H, Jin Y, Wei X, Zhou Y, Wang Z, Wang D, Ren C, Luo H, Wang F, Zhang D, Wang F, Li Y, Yang D, Xu R.

J Cancer. 2016 Mar 26;7(6):694-701. doi: 10.7150/jca.14185. eCollection 2016.

11.

Assessment of the effect of interval from presentation to surgery on outcome in patients with peri-ampullary malignancy.

Amr B, Shahtahmassebi G, Briggs CD, Bowles MJ, Aroori S, Stell DA.

HPB (Oxford). 2016 Apr;18(4):354-9. doi: 10.1016/j.hpb.2015.10.013. Epub 2016 Feb 3.

12.

A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma.

Butler JR, Ahmad SA, Katz MH, Cioffi JL, Zyromski NJ.

HPB (Oxford). 2016 Apr;18(4):305-11. doi: 10.1016/j.hpb.2015.11.009. Epub 2016 Feb 1. Review.

13.

Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy.

Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M, Annamalai A, Nissen NN, Tuli R.

J Gastrointest Oncol. 2016 Apr;7(2):239-47. doi: 10.3978/j.issn.2078-6891.2015.109.

14.

Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.

Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, Hodul PJ, Malafa MP, Springett GM, Centeno BA.

J Gastrointest Oncol. 2016 Apr;7(2):221-7. doi: 10.3978/j.issn.2078-6891.2015.075.

15.

The role of endoscopic ultrasound in pancreatic cancer screening.

Bhutani MS, Koduru P, Joshi V, Saxena P, Suzuki R, Irisawa A, Yamao K.

Endosc Ultrasound. 2016 Jan-Feb;5(1):8-16. doi: 10.4103/2303-9027.175876.

16.

Long-term survival in patients with pancreatic ductal adenocarcinoma.

Stark AP, Sacks GD, Rochefort MM, Donahue TR, Reber HA, Tomlinson JS, Dawson DW, Eibl G, Hines OJ.

Surgery. 2016 Jun;159(6):1520-7. doi: 10.1016/j.surg.2015.12.024. Epub 2016 Feb 2.

PMID:
26847803
17.

State of the art biological therapies in pancreatic cancer.

Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G.

World J Gastrointest Oncol. 2016 Jan 15;8(1):55-66. doi: 10.4251/wjgo.v8.i1.55. Review.

18.

Extended resection in pancreatic metastases: feasibility, frequency, and long-term outcome: a retrospective analysis.

Wiltberger G, Bucher JN, Krenzien F, Benzing C, Atanasov G, Schmelzle M, Hau HM, Bartels M.

BMC Surg. 2015 Dec 11;15:126. doi: 10.1186/s12893-015-0114-1.

19.

Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Pugalenthi A, Protic M, Gonen M, Kingham TP, Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ.

J Surg Oncol. 2016 Feb;113(2):188-93. doi: 10.1002/jso.24125. Epub 2015 Dec 18.

PMID:
26678349
20.

The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.

Ruess DA, Makowiec F, Chikhladze S, Sick O, Riediger H, Hopt UT, Wittel UA.

BMC Surg. 2015 Nov 28;15:123. doi: 10.1186/s12893-015-0110-5.

Items per page

Supplemental Content

Write to the Help Desk